Literature DB >> 23047066

Endoscopic management of Ewing's sarcoma of ethmoid sinus within the AMORE framework: a new paradigm.

Giuseppe Meccariello1, Johannes H M Merks, Bradley R Pieters, Wouter R van Furth, Peerooz Saeed, Reineke A Schoot, Nicole J M Freling, Johannes Bras, Simon D Strackee, Alfons J M Balm, Christos Georgalas.   

Abstract

The Ablative surgery, MOulage brachytherapy and REconstruction) (AMORE) protocol developed in the Academic Medical Center of Amsterdam has been used successfully to treat sarcomas. The use of endoscopic surgery fits well within this framework. A 6-year-old boy presented with Ewing Sarcoma of left ethmoid sinus closest to orbit. The patient underwent neoadjuvant chemotherapy followed by complete endoscopic resection, brachytherapy and reconstruction. Brachytherapy was administered by iridium catheters through limited Lynch-Howarth incision. Skull base defect was reconstructed with a galea flap. The use of endoscopic surgery complemented by neoadjuvant chemotherapy and brachytherapy might maximize tumor control while reducing morbidity.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23047066     DOI: 10.1016/j.ijporl.2012.09.023

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  3 in total

Review 1.  Comprehensive review on rhino-neurosurgery.

Authors:  Werner Hosemann; Henry W S Schroeder
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

Review 2.  Review of advanced catheter technologies in radiation oncology brachytherapy procedures.

Authors:  Jun Zhou; Leonid Zamdborg; Evelyn Sebastian
Journal:  Cancer Manag Res       Date:  2015-07-16       Impact factor: 3.989

Review 3.  Primary Ewing's sarcoma of the ethmoid sinus with orbital extension in a young child: A rare case and review of literature.

Authors:  Nirupama Kasturi; Sandip Sarkar; Tanmay Gokhale; Rajesh Nachiappa Ganesh
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.